Squamous Cell Lung Cancer Clinical Trial
The purpose of this study is to compare early-stage peripheral non-small cell lung cancer lobectomy and sub-lobectomy surgery to evaluate if sub-lobectomy is as feasible and effective for the treatment of early-stage (diameter ≤2cm) peripheral non-small cell lung cancer as lobectomy.
Objectives:To establish a database of patients with early lung cancer surgery,and evaluate
if sub-lobectomy surgery is as feasible and effective as lobectomy surgery in patients with
early-stage peripheral non-small cell lung cancer,by assessing the retainability of lung
function.and improvement of quality of life in those patients.
Outline:This is a prospective, matched, controlled, open, multi-center clinical study.
Select the early-stage peripheral NSCLC 630 patients (diameter≤2cm), according to age and
lesion type (GGO component ratio) two matching factor of 1: 2 assigned to sub-lobectomy
group and lobectomy group.Patients are followed up every 3 months for the first year and
then every 6 months for the other 4 years.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
| Withdrawn |
NCT03346304 -
Photodynamic Therapy for the Prevention of Lung Cancer
|
Phase 2/Phase 3 | |
| Terminated |
NCT01491633 -
Dasatinib in Advanced Squamous Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00087412 -
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00049543 -
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
|
Phase 3 | |
| Active, not recruiting |
NCT04357873 -
Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
|
Phase 2 | |
| Recruiting |
NCT02787473 -
A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00387374 -
Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab
|
Phase 2 | |
| Completed |
NCT00002852 -
Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT05292859 -
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
|
||
| Recruiting |
NCT05550961 -
APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
|
||
| Recruiting |
NCT05607108 -
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT03574818 -
Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001
|
Phase 2 | |
| Suspended |
NCT00909558 -
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
|
Phase 1 | |
| Completed |
NCT00040794 -
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00042835 -
Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
|
Phase 1 | |
| Terminated |
NCT03827850 -
FGFR Inhibitor in FGFR Dysregulated Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01345851 -
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
|
N/A | |
| Withdrawn |
NCT02059967 -
Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC
|
Phase 1 | |
| Completed |
NCT01082549 -
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)
|
Phase 3 |